Multidrug resistance of testis cancers

The study of clinical relevance of P-glycoprotein expression

H. Eid, I. Bodrogi, B. Csókay, E. Oláh, M. Bak

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Germ cell testicular tumors (GCTTs) are very sensitive to anticancer treatment. However some patients ultimately die of their disease due to tumor resistance. Multidrug resistance is mediated by the mdr1 gene product P-glycoprotein (P-gp) which is one important mechanism of drug resistance. This study attempted to examine the correlation between P-gp and tumour progression and to evaluate the clinical relevance of P-gp immunoreactivity in patients with GCTT. Expression of the P-glycoprotein was screened in 48 primary human GCTTs, that have not been treated with chemotherapy, using monoclonal antibody (C219) and immunoenzyme staining. Of the samples from 14 seminomatous germ cell testicular tumors (SGCT) 2 seminomas (14%), and of 34 non-seminomatous tumors (NSGCT) 18 (53%) showed high expression of P-glycoprotein. This difference proved to be significant (P = 0.006). The expression of P-gp showed a statistically significant positive correlation with cancers of advanced stages (P = 0.003) and cancers that showed resistance to chemotherapy (P = 0.0052). Detection of P-gp expression in patients with GCTTs before the application of anti-cancer treatment can be used as a useful prognostic marker to isolate patient subgroups with worse prognosis and less susceptibility to chemotherapy.

Original languageEnglish
Pages (from-to)3447-3452
Number of pages6
JournalAnticancer Research
Volume16
Issue number6 B
Publication statusPublished - 1996

Fingerprint

Testicular Neoplasms
Multiple Drug Resistance
P-Glycoprotein
Neoplasms
Drug Therapy
Seminoma
Clinical Studies
Drug Resistance
Monoclonal Antibodies
Testicular Germ Cell Tumor
Staining and Labeling
Therapeutics
Genes

Keywords

  • Clinical correlation
  • P-glycoprotein immunohistochemistry
  • Testis cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Multidrug resistance of testis cancers : The study of clinical relevance of P-glycoprotein expression. / Eid, H.; Bodrogi, I.; Csókay, B.; Oláh, E.; Bak, M.

In: Anticancer Research, Vol. 16, No. 6 B, 1996, p. 3447-3452.

Research output: Contribution to journalArticle

@article{ace5200787ae4f15a0e15097ba1272d6,
title = "Multidrug resistance of testis cancers: The study of clinical relevance of P-glycoprotein expression",
abstract = "Germ cell testicular tumors (GCTTs) are very sensitive to anticancer treatment. However some patients ultimately die of their disease due to tumor resistance. Multidrug resistance is mediated by the mdr1 gene product P-glycoprotein (P-gp) which is one important mechanism of drug resistance. This study attempted to examine the correlation between P-gp and tumour progression and to evaluate the clinical relevance of P-gp immunoreactivity in patients with GCTT. Expression of the P-glycoprotein was screened in 48 primary human GCTTs, that have not been treated with chemotherapy, using monoclonal antibody (C219) and immunoenzyme staining. Of the samples from 14 seminomatous germ cell testicular tumors (SGCT) 2 seminomas (14{\%}), and of 34 non-seminomatous tumors (NSGCT) 18 (53{\%}) showed high expression of P-glycoprotein. This difference proved to be significant (P = 0.006). The expression of P-gp showed a statistically significant positive correlation with cancers of advanced stages (P = 0.003) and cancers that showed resistance to chemotherapy (P = 0.0052). Detection of P-gp expression in patients with GCTTs before the application of anti-cancer treatment can be used as a useful prognostic marker to isolate patient subgroups with worse prognosis and less susceptibility to chemotherapy.",
keywords = "Clinical correlation, P-glycoprotein immunohistochemistry, Testis cancer",
author = "H. Eid and I. Bodrogi and B. Cs{\'o}kay and E. Ol{\'a}h and M. Bak",
year = "1996",
language = "English",
volume = "16",
pages = "3447--3452",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - Multidrug resistance of testis cancers

T2 - The study of clinical relevance of P-glycoprotein expression

AU - Eid, H.

AU - Bodrogi, I.

AU - Csókay, B.

AU - Oláh, E.

AU - Bak, M.

PY - 1996

Y1 - 1996

N2 - Germ cell testicular tumors (GCTTs) are very sensitive to anticancer treatment. However some patients ultimately die of their disease due to tumor resistance. Multidrug resistance is mediated by the mdr1 gene product P-glycoprotein (P-gp) which is one important mechanism of drug resistance. This study attempted to examine the correlation between P-gp and tumour progression and to evaluate the clinical relevance of P-gp immunoreactivity in patients with GCTT. Expression of the P-glycoprotein was screened in 48 primary human GCTTs, that have not been treated with chemotherapy, using monoclonal antibody (C219) and immunoenzyme staining. Of the samples from 14 seminomatous germ cell testicular tumors (SGCT) 2 seminomas (14%), and of 34 non-seminomatous tumors (NSGCT) 18 (53%) showed high expression of P-glycoprotein. This difference proved to be significant (P = 0.006). The expression of P-gp showed a statistically significant positive correlation with cancers of advanced stages (P = 0.003) and cancers that showed resistance to chemotherapy (P = 0.0052). Detection of P-gp expression in patients with GCTTs before the application of anti-cancer treatment can be used as a useful prognostic marker to isolate patient subgroups with worse prognosis and less susceptibility to chemotherapy.

AB - Germ cell testicular tumors (GCTTs) are very sensitive to anticancer treatment. However some patients ultimately die of their disease due to tumor resistance. Multidrug resistance is mediated by the mdr1 gene product P-glycoprotein (P-gp) which is one important mechanism of drug resistance. This study attempted to examine the correlation between P-gp and tumour progression and to evaluate the clinical relevance of P-gp immunoreactivity in patients with GCTT. Expression of the P-glycoprotein was screened in 48 primary human GCTTs, that have not been treated with chemotherapy, using monoclonal antibody (C219) and immunoenzyme staining. Of the samples from 14 seminomatous germ cell testicular tumors (SGCT) 2 seminomas (14%), and of 34 non-seminomatous tumors (NSGCT) 18 (53%) showed high expression of P-glycoprotein. This difference proved to be significant (P = 0.006). The expression of P-gp showed a statistically significant positive correlation with cancers of advanced stages (P = 0.003) and cancers that showed resistance to chemotherapy (P = 0.0052). Detection of P-gp expression in patients with GCTTs before the application of anti-cancer treatment can be used as a useful prognostic marker to isolate patient subgroups with worse prognosis and less susceptibility to chemotherapy.

KW - Clinical correlation

KW - P-glycoprotein immunohistochemistry

KW - Testis cancer

UR - http://www.scopus.com/inward/record.url?scp=0030519428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030519428&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 3447

EP - 3452

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -